非小细胞肺癌吉西他滨药物耐药相关基因研究进展

被引：10

作者：

陈莹 ^{[1
,2
]}

钱晓萍 ^{[1
,2
]}

刘宝瑞 ^{[1
,2
]}

机构：

[1] 南京医科大学鼓楼临床医学院肿瘤中心

[2] 南京大学医学院附属鼓楼医院肿瘤中心

来源：

中国肺癌杂志 | 2011年 / 05期

关键词：

肺肿瘤; 吉西他滨; 平衡型核苷转运载体1; 核糖核苷酸还原酶亚基1; 脱氧胞苷激酶;

D O I：

暂无

中图分类号：

R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学];

摘要：

随着药物基因组学、药物遗传学的发展,基因指导下个体化治疗成为提高非小细胞肺癌(non-smallcell lung cancer,NSCLC)化疗疗效的有效途径之一。确定药物的相关预测性分子标志物从而指导临床治疗、提高疗效被广泛关注。吉西他滨是目前NSCLC常用化疗药物之一,本文主要阐述了近年来吉西他滨药物耐药相关基因在NSCLC个体化治疗方面的研究进展。

引用

页码：421 / 428

页数：8

共 12 条

[1]

ERCC1、RRM1表达对肺癌患者术后吉西他滨联合顺铂化疗生存趋势的影响 [J].

梁伟军 ;

胡成平 ;

顾其华 ;

宋敏 ;

罗万俊 .

中国肺癌杂志, 2009, 12 (05) :403-407

[2]

肺癌患者RRM1(-37)位点基因多态性及其与临床相关性的研究 [J].

林莉 ;

刘晓晴 ;

宋三泰 ;

王升启 .

中国肺癌杂志, 2008, (06) :784-788

[3]

The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer[J] Tetsuya Oguri;Hiroyuki Achiwa;Hideki Muramatsu;Hiroaki Ozasa;Shigeki Sato;Shigeki Shimizu;Hideko Yamazaki;Tadaaki Eimoto;Ryuzo Ueda Cancer Letters 2007,

[4]

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines[J] Woo Sun Kwon;Sun Young Rha;Yeon Ho Choi;Jung Ok Lee;Kyu Hyun Park;Jae Joon Jung;Tae Soo Kim;Hei-Cheul Jeung;Hyun Cheol Chung Pharmacogenetics and Genomics 2006,

[5]

Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1[J] Scott N. Myers;Rakesh K. Goyal;Jennifer D. Roy;Liane D. Fairfull;John W. Wilson;Robert E. Ferrell Pharmacogenetics and Genomics 2006,

[6]

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter[J] Sara M. Fitzgerald;Rakesh K. Goyal;William R. A. Osborne;Jennifer D. Roy;John W. Wilson;R. E. Ferrell Human Genetics 2006,

[7]

cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer[J] Pascal Sève;John R. Mackey;Sylvie Isaac;Olivier Trédan;Pierre Jean Souquet;Maurice Pérol;Carol Cass;Charles Dumontet Lung Cancer 2005,

[8]

Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway[J] Gee-Chen Chang;Shih-Lan Hsu;Jia-Rong Tsai;Wen-Jun Wu;Chih-Yi Chen;Gwo-Tarng Sheu European Journal of Pharmacology 2004,

[9]

Ribonucleotide reductase: an old target with new potential[J] B.Douglas Smith;Judith E. Karp Leukemia Research 2003,

[10]

Comparison of two human ovarian carcinoma cell lines (A2780/CP70 andMCAS) that are equally resistant to platinum; but differ at codon 118 of the ERCC1gene.[J] J J Yu;K B Lee;C Mu;Q Li;T V Abernathy;F Bostick-Bruton;E Reed International Journal of Oncology 2000,

← 1 2 →